Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.
作者信息
González-Gay Miguel A, Mayo José, Castañeda Santos, Cifrián José M, Hernández-Rodríguez José
机构信息
Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain.
University of Cantabria , Santander, Spain.
出版信息
Expert Opin Biol Ther. 2020 Jul;20(7):717-723. doi: 10.1080/14712598.2020.1770222. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.托珠单抗：从风湿病治疗领域到抗击新冠病毒肺炎这场多面病毒感染之战。
Expert Opin Biol Ther. 2020 Jul;20(7):717-723. doi: 10.1080/14712598.2020.1770222. Epub 2020 Jun 4.
2
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.
3
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.早期识别 COVID-19 细胞因子风暴并使用阿那白滞素或托珠单抗治疗。
Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6.
4
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).嵌合抗原受体 T 细胞（CAR-T）治疗的成年人中的心血管事件。
J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108. doi: 10.1016/j.jacc.2019.10.038.
5
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.COVID-19 感染后复发/难治性多发性骨髓瘤患者抗 BCMA CAR T 治疗：1 例报告。
J Med Case Rep. 2021 Feb 19;15(1):90. doi: 10.1186/s13256-020-02598-0.
6
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
7
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.依那西普作为嵌合抗原受体T细胞疗法后细胞因子释放综合征的一种新的治疗选择。
Exp Hematol Oncol. 2021 Feb 19;10(1):16. doi: 10.1186/s40164-021-00209-2.
8
Macrophage, the potential key mediator in CAR-T related CRS.巨噬细胞，CAR-T相关细胞因子释放综合征中潜在的关键介质。
Exp Hematol Oncol. 2020 Jul 10;9:15. doi: 10.1186/s40164-020-00171-5. eCollection 2020.
9
Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.托珠单抗用于治疗难治性爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤患者单倍体相合供者移植后严重细胞因子释放综合征。
Hematol Oncol. 2018 Feb;36(1):324-327. doi: 10.1002/hon.2481. Epub 2017 Oct 3.
10
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
引用本文的文献
1
The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases.系统性自身免疫性风湿病患者的新型冠状病毒肺炎病程
J Clin Med. 2022 Dec 10;11(24):7342. doi: 10.3390/jcm11247342.
2
Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases.视网膜血管阻塞性疾病的危险因素及治疗策略
J Clin Med. 2022 Oct 27;11(21):6340. doi: 10.3390/jcm11216340.
3
FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.FRAGILE-COLCOVID19：一项基于在老年护理机构中的 COVID-19 老年患者中早期使用秋水仙碱和泼尼松口服联合治疗的临床试验。
Clin Drug Investig. 2022 Nov;42(11):949-964. doi: 10.1007/s40261-022-01201-2. Epub 2022 Sep 29.
4
Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up.重症新型冠状病毒肺炎的成功治疗：1个月随访的白细胞介素-1和白细胞介素-6联合阻断治疗系列病例
Ther Adv Musculoskelet Dis. 2022 Sep 4;14:1759720X221116405. doi: 10.1177/1759720X221116405. eCollection 2022.
5
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.新型冠状病毒肺炎中的外周血T细胞淋巴细胞减少：潜在机制及影响
Immunother Adv. 2021 Jul 2;1(1):ltab015. doi: 10.1093/immadv/ltab015. eCollection 2021 Jan.
6
High-flow Nasal Oxygen Therapy in COVID-19 Critically Ill Patients with Acute Hypoxemic Respiratory Failure: A Prospective Observational Cohort Study.高流量鼻导管给氧疗法用于治疗新冠肺炎合并急性低氧性呼吸衰竭重症患者：一项前瞻性观察性队列研究
Indian J Crit Care Med. 2022 May;26(5):596-603. doi: 10.5005/jp-journals-10071-24167.
7
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.免疫失调和高凝状态作为新冠病毒感染的病理生理背景及秋水仙碱的免疫调节作用
J Clin Med. 2021 Oct 31;10(21):5128. doi: 10.3390/jcm10215128.
8
Biologic Therapy in COVID-19.COVID-19中的生物疗法。
Arch Bronconeumol. 2021 Jan;57:1-2. doi: 10.1016/j.arbres.2020.06.007. Epub 2020 Jun 26.
9
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.托珠单抗超适应证用药联合辅助铁螯合剂治疗重症 COVID-19 肺炎患者的疗效：一项单中心经验。
Medicine (Baltimore). 2021 May 7;100(18):e25832. doi: 10.1097/MD.0000000000025832.
10
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing.生物工程纳米平台对抗 SARS-CoV-2 的意义：从检测到基因组编辑。
Life Sci. 2021 Jun 1;274:119289. doi: 10.1016/j.lfs.2021.119289. Epub 2021 Mar 4.
本文引用的文献
1
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.主要单基因自身炎症性疾病和 PFAPA 综合征的当前治疗选择：循证方法和实用指南建议。
Front Immunol. 2020 Jun 3;11:865. doi: 10.3389/fimmu.2020.00865. eCollection 2020.
2
Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.皮下注射阿那白滞素单一疗法成功治疗重症新型冠状病毒肺炎。
Rheumatology (Oxford). 2020 Aug 1;59(8):2171-2173. doi: 10.1093/rheumatology/keaa318.
3
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
4
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
5
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
6
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.抑制细胞因子风暴：静脉注射阿那白滞素在噬血细胞性淋巴组织细胞增生症或巨噬细胞活化综合征中的应用
Lancet Rheumatol. 2020 Jun;2(6):e358-e367. doi: 10.1016/S2665-9913(20)30096-5. Epub 2020 May 4.
7
Covid-19: Remdesivir is helpful but not a wonder drug, say researchers.研究人员称，新冠病毒：瑞德西韦有帮助，但并非神药。
BMJ. 2020 May 1;369:m1798. doi: 10.1136/bmj.m1798.
8
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
9
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
10
Why the immune system fails to mount an adaptive immune response to a COVID-19 infection.为何免疫系统无法对新冠病毒感染产生适应性免疫反应。
Transpl Int. 2020 Jul;33(7):824-825. doi: 10.1111/tri.13611. Epub 2020 Apr 25.
Zotero 插件